AMRX
Amneal Pharmaceuticals, Inc. Class A · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website amneal.com
- Employees(FY) 7600
- ISIN US03168L1052
Performance
+5.41%
1W
+25.14%
1M
+15.59%
3M
+56.06%
6M
+12.36%
YTD
+227.88%
1Y
Profile
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Investment Analysis Report: AMRX
Overview
AMRX is a pharmaceutical company operating in the Health Technology sector with a market capitalization of $1.81 billion. The company's financial data includes the latest three annual balance sheets, income statements, and cash flow statements, as well as the latest four quarterly balance sheets, income ...
Technical Analysis of AMRX 2024-05-10
Overview:
In analyzing the technical indicators for AMRX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for informed deci...
Recent News & Updates
- 2024-05-15 18:15
Patent Peril: 3 Stocks at Risk From the FTC's Drug Crusade(Investorplace)
- 2024-05-06 15:43
- 2024-05-04 03:05
- 2024-05-03 06:00
Amneal Reports First Quarter 2024 Financial Results(Business Wire)
- 2024-05-03 03:35
- 2024-05-02 22:53
- 2024-05-02 21:30
- 2024-05-02 19:10
- 2024-05-02 18:00
Amneal Reports First Quarter 2024 Financial Results(Businesswire)
- 2024-04-24 17:48
- 2024-04-24 08:00
- 2024-04-23 20:00
- 2024-04-16 08:00
- 2024-04-15 20:00
- 2024-04-15 07:36
- 2024-04-10 08:00
Amneal to Report First Quarter 2024 Results on May 3, 2024(Business Wire)
- 2024-04-09 20:00
- 2024-03-28 16:05
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024(Business Wire)
- 2024-03-28 04:05
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024(Businesswire)
- 2024-03-25 16:05
- 2024-03-25 04:05
- 2024-03-19 18:11
- 2024-03-03 20:07
- 2024-03-01 06:32
- 2024-03-01 06:00
- 2024-02-29 20:30
- 2024-02-29 18:15
- 2024-02-29 17:00
- 2024-02-27 08:00
- 2024-02-26 19:00
Page 1 of 5
previousnext